Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Forms Subsidiary in S. Korea, Sets Sights on Anticancer Drug Sales
December 17, 2013
- AstraZeneca Japan to Draw on Overseas Dapagliflozin Data to Trump SGLT-2 Rivals
December 16, 2013
- Pfizer Japan to Reorganize in January with Stand-Alone Vaccines Unit
December 16, 2013
- Medipal to Venture into Contract PMS Business, Making Medi-Skette Its Wholly Owned Subsidiary
December 16, 2013
- AstraZeneca Japan Sees Annual Growth of Around 8%, Eyes Addition of 160 Reps
December 13, 2013
- Kyowa Kirin, Hisamitsu Launch Cancer Pain Treatment Abstral Sublingual Tablets
December 13, 2013
- IPSN Proposes Life Sciences Business Platform in Tokyo to Be Included in Mr Abe’s Special Zones
December 12, 2013
- Mochida Buys Back 100,000 Shares
December 12, 2013
- New Osaka Logistics Center to Go Live in January: Taisho
December 12, 2013
- Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease
December 12, 2013
- US FDA Advisory Panel Backs Takeda Ulcerative Colitis Drug
December 11, 2013
- Santen Sets Up Local Subsidiary in Singapore
December 11, 2013
- Takeda to Establish New CIO Post, Appoint Former Nestlé Exec
December 11, 2013
- Ono to Launch PI Study on Peptide-Cocktail Vaccine for HCC
December 11, 2013
- GSK Launches Asthma Treatment Relvar
December 11, 2013
- Drug Makers Invest in Developing AD Treatments
December 10, 2013
- Ethical Drug Sales Up 2.5% in October: Crecon Report
December 10, 2013
- Santen Files MAA for Ciclosporin for Dry Eye Disease in Europe
December 10, 2013
- Veep Kawasaki to Be Elevated to President of inVentiv Health Japan
December 9, 2013
- Survey Finds 1.7-Fold Increase in Patients Prescribed DPP-4 Inhibitors Over 2-Year Period: MDV
December 9, 2013
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…